Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially

Indivior Pharmaceuticals, Inc.

2025-Q3 EPS reported $0.85 revenue$881,000,000

SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.
Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.
FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.
Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.
Cash and investments $473M at Q3 end, up $125M from year-end 2024.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-257381
form_type: 8-K
ticker: INDV
cik: 0001625297
company_name: Indivior Pharmaceuticals, Inc.
filed_at: 2025-10-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.965654+00:00
generated_at: 2026-05-17T01:21:05.418247+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-257381
json_url: https://secwatch.observer/filing/0001193125-25-257381.json
markdown_url: https://secwatch.observer/filing/0001193125-25-257381.md
text_url: https://secwatch.observer/filing/0001193125-25-257381.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/0001193125-25-257381-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-257381

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.